CN1113665C - Inflammation diminishing and stone dissolving and exhausting liquid and its production process - Google Patents
Inflammation diminishing and stone dissolving and exhausting liquid and its production process Download PDFInfo
- Publication number
- CN1113665C CN1113665C CN 00117755 CN00117755A CN1113665C CN 1113665 C CN1113665 C CN 1113665C CN 00117755 CN00117755 CN 00117755 CN 00117755 A CN00117755 A CN 00117755A CN 1113665 C CN1113665 C CN 1113665C
- Authority
- CN
- China
- Prior art keywords
- radix
- rhizoma rhei
- emodin
- effect
- liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 28
- 239000004575 stone Substances 0.000 title claims abstract description 18
- 206010061218 Inflammation Diseases 0.000 title abstract description 10
- 230000004054 inflammatory process Effects 0.000 title abstract description 10
- 230000003467 diminishing effect Effects 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title description 2
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000010282 Emodin Substances 0.000 claims abstract description 24
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 claims abstract description 24
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 claims abstract description 24
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 claims abstract description 24
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 claims abstract description 24
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 claims abstract description 24
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 claims abstract description 24
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- 238000000605 extraction Methods 0.000 claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 39
- 239000000284 extract Substances 0.000 claims description 21
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 11
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 claims description 10
- 230000002829 reductive effect Effects 0.000 claims description 9
- 239000006071 cream Substances 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000007789 sealing Methods 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 239000004323 potassium nitrate Substances 0.000 claims description 5
- 235000010333 potassium nitrate Nutrition 0.000 claims description 5
- -1 50 °C of reflux Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 230000002421 anti-septic effect Effects 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 238000007598 dipping method Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 235000003599 food sweetener Nutrition 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 230000001376 precipitating effect Effects 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 3
- 239000005315 stained glass Substances 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 239000003765 sweetening agent Substances 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 59
- 239000003814 drug Substances 0.000 abstract description 12
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 239000001293 FEMA 3089 Substances 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 235000008216 herbs Nutrition 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 20
- 230000002401 inhibitory effect Effects 0.000 description 14
- 241000700159 Rattus Species 0.000 description 13
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Natural products C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 11
- 210000000941 bile Anatomy 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 230000000844 anti-bacterial effect Effects 0.000 description 10
- 230000028327 secretion Effects 0.000 description 10
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 235000012000 cholesterol Nutrition 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 8
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 210000000232 gallbladder Anatomy 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 208000032843 Hemorrhage Diseases 0.000 description 5
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 5
- 241000219061 Rheum Species 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 201000001883 cholelithiasis Diseases 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 244000299790 Rheum rhabarbarum Species 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 4
- 150000004056 anthraquinones Chemical class 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000000387 litholytic effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 241000712461 unidentified influenza virus Species 0.000 description 4
- 230000002485 urinary effect Effects 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 235000008081 Rheum officinale Nutrition 0.000 description 3
- 241000976858 Rheum tanguticum Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- 241000191940 Staphylococcus Species 0.000 description 3
- 241000223238 Trichophyton Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 239000003613 bile acid Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 235000013877 carbamide Nutrition 0.000 description 3
- 230000003177 cardiotonic effect Effects 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 231100000753 hepatic injury Toxicity 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 210000005070 sphincter Anatomy 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VUDQSRFCCHQIIU-UHFFFAOYSA-N 1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl)hexan-1-one Chemical compound CCCCCC(=O)C1=C(O)C(Cl)=C(OC)C(Cl)=C1O VUDQSRFCCHQIIU-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 2
- 239000004382 Amylase Substances 0.000 description 2
- 102000013142 Amylases Human genes 0.000 description 2
- 108010065511 Amylases Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 235000006693 Cassia laevigata Nutrition 0.000 description 2
- YQHZABGPIPECSQ-UHFFFAOYSA-N Citreorosein Chemical compound C1=C(O)C=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YQHZABGPIPECSQ-UHFFFAOYSA-N 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 241000186216 Corynebacterium Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 206010018612 Gonorrhoea Diseases 0.000 description 2
- 101000942967 Homo sapiens Leukemia inhibitory factor Proteins 0.000 description 2
- 208000000913 Kidney Calculi Diseases 0.000 description 2
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010029148 Nephrolithiasis Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000019280 Pancreatic lipases Human genes 0.000 description 2
- 108050006759 Pancreatic lipases Proteins 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 2
- 241000522641 Senna Species 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 208000006568 Urinary Bladder Calculi Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 235000019418 amylase Nutrition 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000003579 anti-obesity Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000003809 bile pigment Substances 0.000 description 2
- 210000003445 biliary tract Anatomy 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000002279 cholagogic effect Effects 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 206010013023 diphtheria Diseases 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000001076 estrogenic effect Effects 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 208000001786 gonorrhea Diseases 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000002475 laxative effect Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 229940116369 pancreatic lipase Drugs 0.000 description 2
- 230000000590 parasiticidal effect Effects 0.000 description 2
- 239000002297 parasiticide Substances 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229940124513 senna glycoside Drugs 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 229940098465 tincture Drugs 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 210000000626 ureter Anatomy 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- LAOOXBLMIJHMFO-UHFFFAOYSA-N 1-[2-(diethylamino)ethylamino]-4-methylthioxanthen-9-one;hydron;chloride Chemical compound Cl.S1C2=CC=CC=C2C(=O)C2=C1C(C)=CC=C2NCCN(CC)CC LAOOXBLMIJHMFO-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- ZXVONLUNISGICL-UHFFFAOYSA-N 4,6-dinitro-o-cresol Chemical group CC1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1O ZXVONLUNISGICL-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010004663 Biliary colic Diseases 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 241000269417 Bufo Species 0.000 description 1
- 208000031868 Calculus ureteric Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000754688 Cercaria Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000144210 Culex pipiens pallens Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000031814 IgA Vasculitis Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102100036721 Insulin receptor Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241000514697 Lepidothamnus laxifolius Species 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 208000010557 Lipid storage disease Diseases 0.000 description 1
- 208000000501 Lipidoses Diseases 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 241000187481 Mycobacterium phlei Species 0.000 description 1
- 241000187480 Mycobacterium smegmatis Species 0.000 description 1
- 241000893976 Nannizzia gypsea Species 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 206010058667 Oral toxicity Diseases 0.000 description 1
- 240000007711 Peperomia pellucida Species 0.000 description 1
- 241000557417 Pimus Species 0.000 description 1
- 235000010450 Pino mugo Nutrition 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 240000007263 Pinus koraiensis Species 0.000 description 1
- 235000011615 Pinus koraiensis Nutrition 0.000 description 1
- 235000008575 Pinus pinea Nutrition 0.000 description 1
- 240000007789 Pinus pinea Species 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010038419 Renal colic Diseases 0.000 description 1
- FCDLCPWAQCPTKC-UHFFFAOYSA-N Rhein Chemical compound C1=CC=C2C(=O)C3=CC(C(=O)O)=CC(O)=C3C(=O)C2=C1O FCDLCPWAQCPTKC-UHFFFAOYSA-N 0.000 description 1
- 241000976888 Rheum hotaoense Species 0.000 description 1
- 241000531795 Salmonella enterica subsp. enterica serovar Paratyphi A Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 101000834072 Shigella flexneri Glutamine synthetase adenylyl transferase Proteins 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 241001149963 Sporothrix schenckii Species 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical class [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000224526 Trichomonas Species 0.000 description 1
- 241001459572 Trichophyton interdigitale Species 0.000 description 1
- 241001480046 Trichophyton schoenleinii Species 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000000014 Ureteral Calculi Diseases 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- MXZRMHIULZDAKC-UHFFFAOYSA-L ammonium magnesium phosphate Chemical compound [NH4+].[Mg+2].[O-]P([O-])([O-])=O MXZRMHIULZDAKC-UHFFFAOYSA-L 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001716 anti-fugal effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000010234 biliary secretion Effects 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000000741 diarrhetic effect Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 229940001501 fibrinolysin Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229940055036 mycobacterium phlei Drugs 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000001819 pancreatic juice Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- FFWOKTFYGVYKIR-UHFFFAOYSA-N physcion Chemical compound C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1O FFWOKTFYGVYKIR-UHFFFAOYSA-N 0.000 description 1
- OISYIJRGMYJBRH-UHFFFAOYSA-N physcione Natural products COc1cc(O)c2C(=O)c3ccc(O)cc3C(=O)c2c1 OISYIJRGMYJBRH-UHFFFAOYSA-N 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000003405 preventing effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 229940069514 rhubarb preparation Drugs 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 1
- 230000001843 schistosomicidal effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 229910052567 struvite Inorganic materials 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229920001864 tannin Chemical class 0.000 description 1
- 239000001648 tannin Chemical class 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention provides inflammation diminishing and stone dissolving and exhausting liquid, which solves the defects that the preparation progress of the traditional medicine is complicated; the cost is high, and ordinary patients are difficult to bear. The present invention is composed of emodin and turpentine oil. The present invention has the advantages of reasonable formula, advanced extraction process, high therapeutic effects, small toxicity and side effects, wide medicinal herbs resources and low price.
Description
The present invention relates to treat Iithiasic antiinflammatory, stone dissolving and exhausting liquid and preparation method thereof.
Calculus is a kind of commonly encountered diseases, as cholelithiasis, renal calculus, traditional therapy has operation and two kinds of oral drugs, because the inconvenience of performing the operation, the patient selects oral medicine usually, existing oral medicine, complicated process of preparation, cost height, often several thousand yuan of courses of treatment, general patient is difficult to bear, and its therapeutic effect is not good.
The objective of the invention is provides a kind of reasonable recipe, extraction process advanced person, curative effect height, toxic and side effects is little, the medicine source is wide, cheap antiinflammatory, stone dissolving and exhausting liquid in order to overcome the shortcoming of existing medicine bottle.
For achieving the above object, the present invention is by the following technical solutions:
A kind of antiinflammatory, stone dissolving and exhausting liquid, its prescription consists of: emodin, Oleum Terebinthinae.
The preparation method of this antiinflammatory, stone dissolving and exhausting liquid, concrete processing step is:
(1) Radix Et Rhizoma Rhei extracts: (1) Radix Et Rhizoma Rhei decoction piece soaks after 24 hours with 5 times of amounts of 2% potassium nitrate, 70% ethanol, 50 ℃ of reflux, extract, of low temperature, each 10-15 minute; Continuous dipping extracts 3 times with method, merges 3 times extracting solution, reclaims ethanol, and concentrate under reduced pressure at low temperature becomes cream; (2) add 3 times of amounts of 70% ethanol again, smash all, leave standstill 12-14 hour precipitated impurities, extract supernatant liquid filtering; Precipitated liquid is with 45% washing with alcohol 2-3 time, and the solubility composition washes out in will precipitating, and filtrate and washing liquid merge, and reclaim ethanol, the cold true one-tenth cream of concentrating under reduced pressure.
(2) Oleum Terebinthinae extraction process: common medical Oleum Terebinthinae redeposition is filtered, and filtrate is contained in the bottle, and the bottle sealing is preserved.
(3) antiinflammatory, stone dissolving and exhausting liquid preparation process: emodin 80mg/kg/ day, Oleum Terebinthinae 0.4ml/kg/ day, mix and add in antiseptic Tween 80, sweetener, two 10ml oral liquids of the packing coloured glass bottle sealing preservation.
The present invention has following characteristics and effect:
One, the medicine characteristics of antiinflammatory stone dissolving and exhausting liquid:
1, this medical instrument has novelty, reasonable recipe: be made up of Radix Et Rhizoma Rhei, Oleum Terebinthinae: have high-efficiency low-toxicity, characteristics that toxic and side effects is little; We increase IBP with antiinflammatory relieving spasm to stop pain, lithodialysis, calculus, increase bile secretion, function of gallbladder promoting, expansion Ao Dishi sphincter and discharge cholelithiasis.Antiinflammatory relieving spasm to stop pain, lithodialysis, calculus increase the urine flow and discharge kidney, ureter, vesical calculus.(1) efficient: as to control cholelithiasis 236 examples altogether, cure 169 examples and account for 71.61%; Produce effects 42 examples account for 17.80%; Effective 21 examples account for 8.90%; Invalid 4 examples account for 1.70%; Total effective rate 98.30%.(2) quick-acting: as after taking medicine 2 days, calculus 121 people to occur and account for 51.27%.(3) nontoxic: to the heart, liver, kidney, the equal avirulence infringement of brain.(4) side effect: it is the calculus reaction that part patient has diarrhoea, slight biliary colic, ureteral colic.
2, our extraction process advanced person: Radix Et Rhizoma Rhei with 2% potassium nitrate, 5 times the amount 70% ethanol, soak after 24 hours, low temperature reflux extracts, the response rate reaches 42%, the purity height, and curative effect improves 46% than similar medicine, serum potassium increases, increased nervous irritability, increase bile secretion, potassium nitrate itself just has the lithodialysis laxative action, and potassium is removed inhibition and the infringement of Radix Et Rhizoma Rhei Senna fruit glycoside to cardiac muscle again.
3, this side has very strong litholytic effect, and Oleum Terebinthinae all has very strong litholytic effect to cholesterol calculus, bilirubin calculus etc.Especially to pigmented calculus 100% dissolving in 60 hours.Radix Et Rhizoma Rhei extracts potassium salt laxative in the solution, and very strong calculus dissolving and excreting effect is also arranged.Reduce bile cholesterol saturation effect, make bile cholesterol be in dissolved state and be difficult for separating out crystallization, the cholesterol calculus dissolving.Adjust normal lipid metabolism in the bile, the control cholesterol calculus forms.Reduce cholesterol and from intestinal, absorbs, reduce HMG-COA reductase activity in the hepatocyte, thereby the synthesizing and from bile, discharge of inhibition cholesterol.Increase the secretion of bile acid and lecithin, the control cholesterol calculus forms.
4, cholagogic and lithagogue effect: promote bile secretion, increase IBP, bilirubin and bile acid content are increased, bile flow obviously increases, and the expansion of Ao Dishi sphincter helps cholagogic and lithagogue.
5, antiinflammatory relieving spasm to stop pain, diuresis and expelling stone effect: dissolving urinary system calculus (calcium oxalate stone, calcium phosphate stone, magnesium ammonium phosphate calculus etc.), kill the urinary system bacterial infection, diminish inflammation, remove the painful contraction of ureter, increase the urine flow, reach diuresis and expelling stone.Control urinary system calculus 257 examples altogether.Ureteral calculus 176 examples wherein, renal calculus 27 examples, multiple calculus 18 examples, vesical calculus 12 examples, calculus of urethra 2 examples, 4 examples are failed to understand at the position.Cure calculus and calculus shadow 186 examples that disappear and account for 72.37%; Produce effects 38 examples account for 14.79% and account for; Effective 25 examples 9.73%; Invalid 8 examples account for 3.11%, total effective rate 96.89%.
6, very strong antibiotic, antifungal, antiviral, parasiticide effect are arranged: remove mucus piece, antibacterial, the epithelial cell that comes off, inflammation exudate in the gallbladder, parasite, foreign body etc. prevents that calculus from forming.
7, very strong anti-inflammatory analgesic effect is arranged: elimination antibacterial, virus, pathogenic microorganism cause ulcer hyperemia, edema inflammatory reaction to gallbladder, biliary pore mucosa, and granulation tissue hyperplasia, and the congestion and edema inflammatory reaction of inhibition and tissue repair effect are arranged.
8, hepatoprotective effect: get rid of hepatic calculus, hepatic injury is had protective effect.
9, anti-tumor of biliary tract and urological cancer effect, immune dual regulation.
10, the effect of stopping blooding, invigorate blood circulation: control gallbladder system and urinary system is hemorrhage, the thrombus dissolving effect.Blood vessel dilating and hypotensive effect.
11, promote pancreatic secretion: prevent acute edema type or downright bad pancreatitic generation of type of acute hemorrhage and development that trypsin or ethanol bring out; And trypsin, pancreatic lipase, pancreatic amylase activity there is obvious inhibitory action.Suppressing three kinds of enzymes is the pancreatitic bases of treatment, and pepsin activity is not had influence.Helping biliary tract is that inflammation is eliminated, and calculus is discharged, the reparation as early as possible of tissue.
The pharmacological action of two, antiinflammatory, lithodialysis, calculus removal liquid:
The Radix Et Rhizoma Rhei pharmacological action
(1) choleretic effect: Radix Et Rhizoma Rhei can promote the bile secretion of Canis familiaris L., and the content of bilirubin and bile acid is increased.Rat experiment proves that big yellow fluid, alcohol extract, Radix Et Rhizoma Rhei decoct have all made bile flow obviously increase, and its peak is in administration 30 minutes.Observe to find to take with B ultrasonic give birth to, behind the Radix et Rhizoma Rhei (processed) 0.5 and 1 hour gallbladder obviously greater than before the clothes Radix Et Rhizoma Rhei, also can promote to test the biliary secretion of acute suppurative cholecystitis, the composition that the prompting Radix Et Rhizoma Rhei is significantly increased bile secretion also has it to suppress composition, and this preparation research and clinical practice for Radix Et Rhizoma Rhei provides certain clue.
(2) discharge function: Radix Et Rhizoma Rhei has discharge function, is used for the treatment of constipation due to dry stool, constipation with heat retention, generally can discharge loose stool in 6-19 hour after medication.The Senna fruit glycoside is the effective ingredient of Radix Et Rhizoma Rhei diarrhea inducing, and Radix Et Rhizoma Rhei has excited and suppresses the gastrointestinal dual function, and the material base of this effect is exactly Senna fruit glycoside and tannin class.
(3) to the influence of gastric and duodenal ulcers: Radix Et Rhizoma Rhei can be treated and be prevented the hemorrhage of stress gastric ulcer, shows as extent of hemorrhage and obviously alleviates, and hemorrhagic focus, the duty of hemorrhagic focus face obviously reduce, and its effect is similar to cimetidine.
(4) to the influence of intestinal tube electrical activity and contraction movement: Radix Et Rhizoma Rhei has tangible excitation to the electrical activity of whole colon, characteristics are the gregariousness discharge, peak electricity frequency obviously speeds, amplitude obviously increases, this explanation Radix Et Rhizoma Rhei hinders the colonic moisture absorption by excited intestinal electrical activity, accelerates the discharge of colonic contents and brings into play its discharge function, and low dose makes the inhibition of colon electrical activity, heavy dose makes the excitement of intestinal electrical activity, then occurs excited earlier back sometimes and suppresses phenomenon.Bring into play its discharge function by the m receptor that acts in the intestinal tube.
(5) to the influence of liver: Radix Et Rhizoma Rhei has significant protective effect to experimental hepatic injury.Radix Et Rhizoma Rhei can reverse significantly that the fat that occurs in the hepatic tissue that CCL4 causes drips and fibrosis, microsome swelling, ridge obviously descend, rough endoplasmic reticulum destroys, ribosome significantly comes off etc.The hepatic injury that Radix Et Rhizoma Rhei causes CCL4 truly has prevention and therapeutical effect.
(6) promote the pancreatic secretion effect: experimental results show that acute edema type or downright bad pancreatitic generation of type of acute hemorrhage and development that Radix Et Rhizoma Rhei can prevent that trypsin or ethanol from bringing out.Tissue hyper-microstructure confirms that it also has the obvious treatment effect to the pancreas in rat inflammation that D-two methyllanthionines cause.In 30 minutes, pancreatic juice all obviously increases after administration for Radix Et Rhizoma Rhei decoct and preparation, and dosage strengthens, and effect is strengthened, and it is more of a specified duration to hold time.The Radix Et Rhizoma Rhei decoct in vitro reaches under the nearly gastrointestinal tract environment of simulation, and the activity of trypsin, pancreatic lipase and pancreatic amylase is had the obvious suppression effect, and to the not influence of pepsic activity.
Radix Et Rhizoma Rhei and extract thereof have the effect of significant promotion pancreatic secretion, may be relevant with the lax Ao Dishi sphincter tone of Radix Et Rhizoma Rhei, and Radix Et Rhizoma Rhei may be the pancreatitic basis of rhubarb treatment to the influence of three kinds of digestive enzyme of pancreatic secretion.
2, to the influence of pathogenic microorganism:
(1) antibacterial action: experimental results show that Radix Et Rhizoma Rhei all has in various degree inhibitory action to staphylococcus, Hemolytic streptococcus, diphtheria corynebacterium, bacillus subtilis, Mycobacterium phlei, brucella, bacillus pestis, typhoid fever, Salmonella paratyphi, dysentery bacterium, deep shape bacillus, bacillus smegmatis, gonorrhea diplococcus etc., the most responsive with staphylococcus, gonorrhea diplococcus especially.3-carboxyl rhein, hydroxyl aloe-emodin, hydroxyemodin three antibacterial action are the strongest.Chrysophanic acid, emodin, aloe-emodin are 1.5-25mcg/ml to the inhibition concentration of staphylococcus, streptococcus, diphtheria corynebacterium, bacillus subtilis, anthrax bacillus, Bacillus typhi etc.Emodin, aloe-emodin are respectively 15mg/l, 480mg/l, 120mg/l and 7.5mg/l, 600mg/l, 60mg/l to staphylococcus aureus 209P, escherichia coli, shigella flexneri at external minimum inhibitory concentration.To clinical isolating 119 strain staphylococcus aureus minimum inhibitory concentrations, emodin is 20-160mg/l, and aloe-emodin is 10-80mg/l.After the inducible resistance test, aloe-emodin produces drug resistance, and emodin does not produce drug resistance.Radix Et Rhizoma Rhei antibacterial action mechanism mainly is to bacterial cell nucleic acid and protein synthesis and glycometabolic inhibitory action.
(2) antifungic action: the extractum of Radix Et Rhizoma Rhei decoct and water, alcohol, ether has inhibitory action to some common pathogenic funguses in vitro, and responsive strain has oidium schoenleinii and Mongolian mutation thereof, Trichophyton concentricunm, trichophyton, star nocardia, sufficient sole of the foot trichophyton, acrothesium floccosum, trichophyton gypseum, trichophyton interdigitale, sporotrichum schenckii etc.
(3) antivirus action: the susceptible poison of Radix Et Rhizoma Rhei decoct convection current has stronger inhibitory action.
(4) parasiticide effect: the Radix Et Rhizoma Rhei leachate can kill histolytica distortion protozoon respectively in the concentration of 1: 5000 and 1: 1000, can kill Trichomonas hominis at 1: 5000, and a little less than the inhibition to intestinal infusorian and Wan Shi lip whipworm.Emodin has 40% suppression ratio to the mouse infection schistosomicide.The concentration of wild Radix Et Rhizoma Rhei 1% can make cercaria dead in 90 minutes.5% Radix Et Rhizoma Rhei leachate can make culex pipiens pallens larvae dead 50% in 48 hours.
3, to the influence of cardiovascular system:
(1) to the influence of heart: the emodin low dose is strengthened the isolated heart contractility, and heavy dose then suppresses.Radix Et Rhizoma Rhei can make the MAP amplitude of heart increase, and climbing speed speeds, and myocardial contraction obviously strengthens, and proves that Radix Et Rhizoma Rhei has significantly cardiotonic.Increase that K+ concentration can weaken the toxic action of heavy dose of Radix Et Rhizoma Rhei to heart in the extracellular fluid, the cardiotonic of Radix Et Rhizoma Rhei may with the Na+ that suppresses on the cell membrane, the K+-ATP enzyme is relevant.Rhubarb polyoses can make the normal rat blood pressure drops, and decreased heart rate makes normal and depleted Bufo siccus cardiac contractile force and the cardiac output of exsomatizing increases, the prompting cardiotonic may be by suppress Myocardial Na+, the K+-ATP enzyme is realized.
(2) to the influence of blood vessel: Radix Et Rhizoma Rhei preserved material, tincture and emodin all have the effect that brings high blood pressure down.The Radix Et Rhizoma Rhei tincture can make rabbit ear vasodilation.
(3) stop blooding and the effect of invigorating blood circulation: the hemostasis effective ingredient α-catechin of Radix Et Rhizoma Rhei and gallic acid can reduce the activity of antithrombase II (AT II), the content of rising α 2-MG (alpha2 Macroglobulin), the vigor that suppresses fibrinolysin and plasminogen activin competitively, the fibrinolytic vigor is descended, and the adhesiveness of platelet increasing and ability of aggregation, thereby quicken hemostasis.
(4) blood fat reducing and antiobesity action: rhubarb polyoses can make egg yolk and the inductive hyperlipidemia mice serum of high lipid food and total cholesterol of liver (TC), triglyceride (TG) obviously reduce, may be relevant with anorexia and cathartic.There is the effect of tangible reduction serum total cholesterol at the alcohol extraction position of Radix Et Rhizoma Rhei.Living, Radix Et Rhizoma Rhei has tangible antiobesity action, and its blood fat reducing and fat-reducing composition may be anthraquinone class, catechin compounds, and polysaccharide also has these effects.
4, the chrysophanic acid of antitumor action: 5mg/kg and emodin are respectively 76% and 73% to the suppression ratio of murine melanoma.Emodin has significant competitive inhibition to cheese ammonia enzyme, and this inhibitory action may be one of mechanism of action of Radix Et Rhizoma Rhei melanoma.
5, to Immune Effects: emodin and aloe-emodin lumbar injection 70mg/kg7d have in various degree inhibitory action to normal mouse immune system, as alleviate the weight of immune organ, reduce production of antibodies, suppress carbon clearance function and peritoneal macrophage phagocytic function, reduce leukocyte count, delayed hypersensitivity due to inhibition 2, the 4 dinitro phenalgins (DNCB).
6, to the influence of kidney: Radix Et Rhizoma Rhei has the effect of non-protein nitrogen in the tangible reduction blood, this effect may be owing to reduced the absorption of intestinal to amino nitrogen (raw material of urea synthesis), and essential amino acids concentration is raise, utilize the catabolite of vivo acid---ammonia synthesis protein, thus liver, nephridial tissue urea synthesis are reduced; Radix Et Rhizoma Rhei also suppresses the decomposition of body protein, with the content of minimizing blood urea nitrogen and creatinine, and the drainage of promotion carbamide and creatinine.
7, antiinflammatory action: Radix Et Rhizoma Rhei has the obvious suppression effect to multiple zoopery inflammation, and oral decoct can significantly suppress Oleum Tiglii and cause mice ear inflammatory edema, rat formaldehyde, Ovum Gallus domesticus album pedal swelling, the granuloma induced by implantation of cotton pellets hypertrophy of mice and rat.Rheum hotaoense C. Y. Cheng et C. T. Kao extractum all has significant inhibitory effect to rat Ovum Gallus domesticus album and formaldehyde pedal swelling and mouse experiment peritonitis.
8, analgesic cooling effect: after gavaging the Radix Et Rhizoma Rhei water decoction for the rabbit of normal and Diplococcus pneumoniae infectious fever, observe pathologic fever in rabbit body temperature (anus temperature) and obviously descend, simultaneously as seen in the ventriculus tertius perfusate PGE content obviously reduce.Radix Et Rhizoma Rhei may be brought into play cooling effect by influencing PGE.
9, anti-aging effects: the rheum rhabarbarum polysaccharide that extracts in the rheum rhabarbarum can obviously prolong average life and the maximum life span of fruit bat.The rheum rhabarbarum polysaccharide also can increase swimming time and the hypoxia-bearing capability of 2-3 monthly age mice, shows that the rheum rhabarbarum polysaccharide has multiple effects such as strong.
10, to the influence of diabetes: the type i diabetes rat drug resistance to insulin disappearance that Radix Et Rhizoma Rhei can make streptozotocin cause, ERYTHROCYTE INSULIN maximum combined power raises, and serum insulin levels reduces.Radix Et Rhizoma Rhei has similar effect to alloxan diabetes rats.Radix Et Rhizoma Rhei can improve the Insulin receptor INSR adhesion, improves sugar, lipoidosis and hyperinsulinemia.Illustrating that acceptor binding force reduces and the information conductive impairment is the basis of development of insulin resistance, show that Radix Et Rhizoma Rhei is at acceptor levels treatment NIDDM, is the atherosclerotic ideal medicament of prevent diabetes.
11, estrogen-like effects: emodin has estrogen-like effects, can make the rapid restorative cycle of castration female rats, and clinic trial also has the effect of estrone sample.
12, diuresis: Radix Et Rhizoma Rhei crude drug and chrysophanic acid, emodin all have diuresis.
13, physiological disposition:
(1) absorb: adopt the absorption of isotope-labelling method research emodin, the single oral dose emodin, radioactivity increases sharply in the PBF, reaches maximum in 2 hours, then drops to peakedly 30% in 24 hours, then slowly descends later on.(2) distribute: after rhubarb anthraquinone absorbs, serve as maximum with liver, kidney, gallbladder in vivo, isotope-labelling method proves that emodin mainly is distributed in kidney, mesentery and the fat, in muscle, brain, small intestinal and the colon seldom.(3) drain: rhubarb anthraquinone is discharged by excrement and urine, accounts for 23.4% and 22.8% of intake respectively, and it serves as maximum discharging with 2-4 hour through urine, discharges about 61% in 8 hours.
14, toxic and side effects
(1) acute toxicity: the injection of Radix Et Rhizoma Rhei ether extract mouse peritoneal, dosage reaches 40g (crude drug)/kg, observes 72 hours, does not see dead and unusual.Rhubarb preparation mouse subcutaneous injection LD50 is 4.052g/kg and 2g/kg.With age, CPC was every group of 6 lumbar injections of mice all around, the LD50 of the Diluted Alcohol extractum of Radixet Rhizoma Rhei, Rheum tanguticum, second-class Rheum tanguticum is 0.25-0.5g/kg; The Rheum tanguticum decoction pieces, etc. the about 0.25g/kg of LD50 of outer Radix Et Rhizoma Rhei; The Radix Et Rhizoma Rhei oral toxicity is injected little.The LD50 of Radix Et Rhizoma Rhei anthraquinone analog derivative mouse stomach, emodin are that 0.56g/kg, physcione are 1.15g/kg, and chrysophanol is 10g/kg.
(2) long term toxicity:
1. gastrointestinal is influenced: irritate the stomach rat with 200% Radix Et Rhizoma Rheidecocted solution, every day 3-4.5ml, scanning electron microscopic observation has the different irritable inflammation of degree to its harmonization of the stomach large intestine after 4,5 days, thinks that this is to cause indigestion and loss of appetite, diarrheal reason.2. to the immunologic function inhibitory action: have the report Radix Et Rhizoma Rhei to irritate " deficiency syndrome " rat due to the stomach, immune organs such as thymus, spleen, mesenteric lymph node diminish, alleviate, and also cause the obvious atrophy of thymus in mice, Golden Hamster.3. to the influence of reproductive system: Radix Et Rhizoma Rhei was irritated the stomach rat 7.5g/kg14 days, and visible female Mus period of sexual maturity obviously delays, and uterus, ovary weight alleviate.
The Oleum Terebinthinae pharmacological action
(1) effect of Oleum Terebinthinae character and usage: be colourless or faint yellow clear liquid.Smelly special, store with the passing of time or be exposed at that foul smell strengthens, is dissolved in ethanol, can mixes arbitrarily with glacial acetic acid in the air, skin irritation, sterilize, draw red effect, preparation kentish liniment, be used for myalgia, rheumatic arthritis, peripheral neuritis, sprain, erythema nodosum, anaphylactoid purpura etc. are to 60 hours lithodialysis rates 100% of bile pigments type calculus.
(2) Oleum Terebinthinae litholytic effect:
Experiment in vitro confirms that Oleum Terebinthinae Emulsion can make the cholelithiasis dissolving of taking from the cholelithiasis patient, make bile pigments type calculus add all dissolvings in back 60 hours at Emulsion, so Oleum Terebinthinae Emulsion has good litholytic effect.
(3) antibiosis and antiviral functions:
1, antibacterial action
The ammonia extraction thing of Pinus koraiensis is to mouse peritoneal or intravenously administrable, the animal dead that escherichia coli, pneumobacillus, staphylococcus aureus are caused has tangible antagonism, and different alkaline extracts also have significant antibacterial activity to the mouse infection that staphylococcus aureus, escherichia coli, Pseudomonas aeruginosa, pneumobacillus, Candida albicans cause.The generation that antibacterial activity thing intraperitoneal administration can be induced differentiation inducing factor (DIF), after the administration 1-2 hour, peak, and can make polymorphonuclear cell (PMN) accumulation that the generation of peritoneum emigrated cell and adherent cell superoxides is increased, the activation of PMN plays an important role in the pine extract antibacterial action.
2, anti-AIDS-virus effect
The extract PC6 of Pimus parviflora Sieb et Zucc is through experiment in vitro, can suppress duplicating of HIV, virus breeding is suppressed, reaching 80% Cmin that suppresses effect is 3mg/ml, HIV-1 in U937 people's lymphocytic cancer cell is also shown obvious inhibitory action, PC6 can suppress the proteic expression of HIV-1 in the cem cell, and PC6 can suppress HIV-1 transcribing and translating in cem cell, and gene expression also has inhibitory action to LTR guiding DNA at transcriptional level.PC6 can produce a kind of solable matter to the pepsin sensitivity by inducing T cell (CEM), this material is that PC6 produces the reason that inhibition HIV-1 duplicates effect, this PC6 inductive HIV-1 inhibitive factor effect and known granulocyte/macrophage activating factor (MAF) (GM-CSF), cytokine 3 (IL-3), β-transforming factor (TNF-β) is irrelevant with the effect of cachectin (TNF-α), so the inductive this anti-HIV-1 material of PC6 may be a kind of new immunologic active material.
3, resisiting influenza virus and other effect
Antibacterial activity composition lignin has the effect of resisiting influenza virus too.Can obviously suppress the growth of influenza virus, the plaque due to the influenza virus is reduced, can significantly suppress the synthetic of virus protein in the infection cell, reduce the activity of the RNA polymerase that viral RNA relies on.
(4) antitumor action:
Its anti-tumor activity size is relevant with acid power, the acid polysaccharide of NaOH extract wherein, and anti-tumor activity is the strongest, can obviously suppress the growth of sarcoma cell, even causes the degeneration and the necrosis of tumor.
(5) to the immune system effect:
Polysaccharose substance can activate mouse macrophage, and the hot water extract can improve the Fc receptor active, and acidic extraction thing energy significant stimulation mice and isolated rat splenocyte DNA's is synthetic, and this acidic extraction thing has immunologic enhancement.
(6) toxic and side effects:
Siberian dwarf pine leaf volatile oil mice LD50 is 0.577 ± 0.056ml/kg; The fruit of Pinus pinea is oral to cause systemic allergic report.
Below in conjunction with embodiment the present invention is further described.
The prescription of this antiinflammatory, stone dissolving and exhausting liquid consists of: emodin, Oleum Terebinthinae.
Its preparation method is realized according to following processing step:
(1) Radix Et Rhizoma Rhei extraction process: (1) Radix Et Rhizoma Rhei decoction piece soaks after 24 hours with 5 times of amounts of 2% potassium nitrate, 70% ethanol, 50 ℃ of reflux, extract, of low temperature, each 10-15 minute; Continuous dipping extracts 3 times with method, merges 3 times extracting solution, reclaims ethanol, and concentrate under reduced pressure at low temperature becomes cream.The response rate reaches 42%.(2) for purity is higher, add 3 times of amounts of 70% ethanol again, smash all, leave standstill 12-14 hour precipitated impurities, extract supernatant liquid filtering; Precipitated liquid is with 45% washing with alcohol 2-3 time, and the solubility composition washes out in will precipitating, and filtrate and washing liquid merge, and reclaim ethanol, the cold true one-tenth cream of concentrating under reduced pressure.
(2) Oleum Terebinthinae extraction process: commercially available medical Oleum Terebinthinae redeposition is filtered, and filtrate is packed in the bottle, preserves the bottle sealing anti-oxidation to prevent.
(3) antiinflammatory stone dissolving and exhausting liquid preparation process
Use according to clinical repetition test and checking, select the best safety consumption for use: emodin 80mg/kg/ day, Oleum Terebinthinae 0.4ml/kg/ day, mix in adding antiseptic Tween 80, sweetener, two 10ml oral liquids of the packing coloured glass bottle, sealing is preserved.
Claims (2)
1. an antiinflammatory, stone dissolving and exhausting liquid, its component is: emodin, Oleum Terebinthinae, its composition are emodin 80mg, Oleum Terebinthinae 0.4ml.
2. the preparation method of an antiinflammatory, stone dissolving and exhausting liquid, concrete processing step is:
(1) Radix Et Rhizoma Rhei extracts: (1) Radix Et Rhizoma Rhei decoction piece soaks after 24 hours with 5 times of amounts of 2% potassium nitrate, 70% ethanol, 50 ℃ of reflux, extract, of low temperature, each 10-15 minute; Continuous dipping extracts 3 times with method, merges 3 times extracting solution, reclaims ethanol, and concentrate under reduced pressure at low temperature becomes cream; (2) add 3 times of amounts of 70% ethanol again, smash all, leave standstill 12-14 hour precipitated impurities, extract supernatant liquid filtering; Precipitated liquid is with 45% washing with alcohol 2-3 time, and the solubility composition washes out in will precipitating, and filtrate and washing liquid merge, and reclaim ethanol, the cold true one-tenth cream of concentrating under reduced pressure.
(2) Oleum Terebinthinae extraction process: common medical Oleum Terebinthinae redeposition is filtered, and filtrate is contained in the bottle, and the bottle sealing is preserved.
(3) antiinflammatory, stone dissolving and exhausting liquid preparation process:, mix and add in antiseptic Tween 80, sweetener, two 10ml oral liquids of the packing coloured glass bottle sealing preservation with the ratio of emodin 80mg, Oleum Terebinthinae 0.4ml.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00117755 CN1113665C (en) | 2000-06-01 | 2000-06-01 | Inflammation diminishing and stone dissolving and exhausting liquid and its production process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00117755 CN1113665C (en) | 2000-06-01 | 2000-06-01 | Inflammation diminishing and stone dissolving and exhausting liquid and its production process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1286981A CN1286981A (en) | 2001-03-14 |
| CN1113665C true CN1113665C (en) | 2003-07-09 |
Family
ID=4587018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 00117755 Expired - Fee Related CN1113665C (en) | 2000-06-01 | 2000-06-01 | Inflammation diminishing and stone dissolving and exhausting liquid and its production process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1113665C (en) |
-
2000
- 2000-06-01 CN CN 00117755 patent/CN1113665C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1286981A (en) | 2001-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1049287B (en) | Topical application containing anemonin as effective component for treating aseptic inflammation and manufacturing method thereof | |
| CN109045061A (en) | Application of the Dendrobium officinale polysaccharide in preparation treatment osteoarthritis drugs | |
| CN1113665C (en) | Inflammation diminishing and stone dissolving and exhausting liquid and its production process | |
| EP1231928B1 (en) | Phytotherapeutic composition | |
| CN1562195A (en) | Mediciation for curing chronic kidney function failure and its prepn. method | |
| CN117717152A (en) | Peptide zinc chelating agent health food for protecting liver and nourishing stomach and preparation method thereof | |
| CN111840448B (en) | Preparation method and application of anti-chapping compound traditional Chinese medicine liposome | |
| CN1488394A (en) | Chinese medicine cap sule for treating prostatic disorders | |
| CN112121123A (en) | Spray for relieving gout and preparation method thereof | |
| CN101564453A (en) | Medicine for treating chronic nonspecific ulcerative colitis and preparation method thereof | |
| CN1197595C (en) | Chinese medicine preparation for broad-spectrum inflammation relieving, disinfecting, erosion prevention and muscle growing | |
| CN1739767A (en) | Compound recipe capable of protecting liver and improving symptoms of hepatosis | |
| CN1136869C (en) | Recovery capsule for hepatitis and its preparing process | |
| CN118634186B (en) | Traditional Chinese medicine suppository for treating acute pancreatitis and preparation method thereof | |
| CN103690771B (en) | Be used for the treatment of medicine of lamb colibacillosis and preparation method thereof | |
| CN109125703A (en) | A kind of pharmaceutical composition and preparation method thereof for treating vaginitis | |
| CN1397315A (en) | Medicine for treating diseases of liver, gallbladder and kidney and its preparing process | |
| CN117482198A (en) | A kind of Wanxiang fruit environmentally friendly enzyme that inhibits gum bleeding, its preparation method and its application | |
| CN1682892A (en) | A kind of Tengdan capsule for treating hypertension | |
| CN121059723A (en) | A traditional Chinese medicine formula for treating surgical wounds after high-level perianal abscess. | |
| CN117281740A (en) | A liver-protecting traditional Chinese medicine composition and its preparation method and application | |
| CN1280007A (en) | Jew's-ear blood fat regulating capsule | |
| WO2005092352A1 (en) | A Producing Method and Applications of Chinese Medicine Liposome Preparation for Treating Viral Hepatitis B and Preventing and Curing Fibration of Liver Cell | |
| CN1413730A (en) | Shugan injection and its preparation technology | |
| CN108030897A (en) | A kind of Chinese medicine ferment for treating prostate cancer and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |